Table: Santen Pharm -2024/25 group results (IFRS)
13/05/2025 07:34
May 13 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2025 Mar 31, 2024 Mar 31, 2026 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULT FORECAST H1 FORECAST
Sales 300.00 301.97 294.00
(-0.6 pct) (+8.2 pct) (-2.0 pct)
Operating 46.88 38.54 44.00
(+21.6 pct) (-6.1 pct)
Pretax 33.50
(-6.6 pct)
Net 36.26 26.64
(+36.1 pct)
EPS Basic 103.98 yen 72.59 yen 102.66 yen
EPS Diluted 103.68 yen 72.37 yen
Ann Div 36.00 yen 33.00 yen 38.00 yen
-Q2 Div 17.00 yen 16.00 yen 19.00 yen
-Q4 Div 19.00 yen 17.00 yen 19.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T